+40.9%
TTWO vs MRNA
-67.9%
+108.8%
-51.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.7% | +5.4% | -6.1% | -0.8% |
| 7D | +0.4% | -1.1% | +1.4% | +0.4% |
| 30D | -11.3% | +126.1% | -137.4% | -14.9% |
| 3M | +1.6% | +190.0% | -188.4% | -4.6% |
| 6M | +2.1% | +157.2% | -155.2% | -3.6% |
| YTD | -15.8% | +388.2% | -404.0% | -24.5% |
| 1Y | -12.6% | +467.0% | -479.6% | -22.8% |
| 3Y | +48.2% | +36.1% | +12.1% | +42.5% |
| All | +40.9% | -67.9% | +108.8% | +34.3% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling